Cross-national price differences for pharmaceuticals: how large, and why?
Cross-national price differences for pharmaceuticals: how large, and why?
复制标题
DOI：
10.1016/s0167-6296(99)00039-9
复制
发表时间：
2000-03-01
影响因子：
3.5
通讯作者：
Chao, LW
中科院分区：
文献类型：
--
作者：
Danzon, PM;Chao, LW
双边药品价格和数量指数基于七个国家（美国、加拿大、法国、德国、意大利、日本和英国）的综合数据，驳斥了美国加权指数（Laspeyres）中美国药品价格远高于其他国家的传统观点。以前的药品价格比较因不具代表性的样本和未加权的指数而存在偏差。准特征回归表明，跨国价格差异反映了产品特征及其隐含价格的差异，从而反映了监管制度；严格的价格监管系统地降低了旧分子和全球扩散分子的价格。在监管较少的国家，一般竞争会降低价格，而这些国家的需求也具有更大的价格弹性。 (C) 2000 Elsevier Science B.V. 保留所有权利。
Bilateral drug price and quantity indexes, based on comprehensive data for seven countries (US, Canada, France, Germany, Italy, Japan and the UK), refute the conventional wisdom that US drag prices are much higher than elsewhere, for Laspeyres (US-weighted) indexes. Previous drug-price comparisons are biased by unrepresentative samples and unweighted indexes. Quasi-hedonic regression shows that cross-national price differences reflect differences in product characteristics and in their implicit prices, which reflect the regulatory regime; Strict price regulation systematically lowers prices for older molecules and globally diffused molecules. Generic competition lowers prices in less-regulated regimes, which also have more price-elastic demand. (C) 2000 Elsevier Science B.V. All rights reserved.